News

Read our latest articles.

EPIK Biosciences Advances Combination Medicines Across Ketamine-Based and DXM-Based Programs, Supported by 34 Provisional Drug Patent Applications

Over 20 filings are ketamine-based and over 5 are dextromethorphan (DXM)-based; applications total more than 2,700 pages of scientific and technical data; Company expects to disclose the full combination portfolio later this year AUSTIN, Texas, Sept. 10, 2026 (GLOBE...

EPIK Biosciences Launches to Pioneer Ketamine-Powered Psychedelic Therapies to Transform Treatment of Mental Health, Pain, and Addiction

Advancing synergistic combination medicines, non-opioid solutions for chronic pain, neuropsychiatric disorders, and substance use disorders using patient-friendly delivery methods. AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- EPIK Biosciences (“EPIK” or the...